NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) ("Rain"), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. ("Pathos") will ...
In a single news cycle, Pathos AI announced two simultaneous drug licensing agreements worth up to $2.3 billion in combined milestones — and disclosed that it is targeting a $300 million Series E ...
Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic Pathos assumes responsibility for early clinical development of ...
CHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning ...
Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical
Aug 4 (Reuters) - New York City-based Pathos AI will pay $125 million upfront to a subsidiary of Alphamab Oncology (9966.HK), opens new tab for rights to an experimental drug for a type of breast ...
Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
If you think high-end audio has to be boxy and/or kinda masculine, check out Pathos Acoustics wares. We think it’s hot stuff, and when we’ve heard it at shows the sound was always pretty impressive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results